KineMed, Inc. Announces Agreement With Amgen (AMGN) to Develop Kinetic Biomarkers of Brain Proteinopathies
10/15/2013 9:52:48 AM
EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) today announced an agreement with Amgen to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases.
Help employers find you! Check out all the jobs and post your resume.